{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aflibercept+8+mg", "query": { "intervention": "Aflibercept 8 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 55, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aflibercept+8+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-17T16:18:45.511Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04611152", "title": "A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "KSI-301", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" }, { "name": "Sham Procedure", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kodiak Sciences Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 460, "start_date": "2020-09-30", "completion_date": "2023-08-31", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-09-17T16:18:45.511Z", "location_count": 48, "location_summary": "La Jolla, California • Redlands, California • Santa Maria, California + 44 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Lakewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04611152" }, { "nct_id": "NCT03386474", "title": "Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "Brolucizumab 6 mg", "type": "DRUG" }, { "name": "Aflibercept 2 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 151, "start_date": "2018-01-15", "completion_date": "2018-09-06", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-09-17T16:18:45.511Z", "location_count": 63, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Arcadia, California + 56 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03386474" }, { "nct_id": "NCT05275205", "title": "Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "UBX1325 injection 50 μL", "type": "DRUG" }, { "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Unity Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 51, "start_date": "2022-03-02", "completion_date": "2023-07-25", "has_results": true, "last_update_posted_date": "2024-08-07", "last_synced_at": "2026-09-17T16:18:45.511Z", "location_count": 14, "location_summary": "Beverly Hills, California • Huntington Beach, California • Longmont, Colorado + 11 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Longmont", "state": "Colorado" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05275205" }, { "nct_id": "NCT04049266", "title": "A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Wet Macular Degeneration" ], "interventions": [ { "name": "KSI-301", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" }, { "name": "Sham Procedure", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kodiak Sciences Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 559, "start_date": "2019-10-08", "completion_date": "2022-04-26", "has_results": true, "last_update_posted_date": "2024-07-18", "last_synced_at": "2026-09-17T16:18:45.511Z", "location_count": 59, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04049266" }, { "nct_id": "NCT00789477", "title": "DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Laser Photocoagulation", "type": "PROCEDURE" }, { "name": "Intravitreal Aflibercept Injection", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2008-12", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2014-09-09", "last_synced_at": "2026-09-17T16:18:45.511Z", "location_count": 42, "location_summary": "Artesia, California • Beverly Hills, California • Mountain View, California + 38 more", "locations": [ { "city": "Artesia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00789477" }, { "nct_id": "NCT07440225", "title": "A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Macular Degeneration", "Age-Related Macular Degeneration", "Choroidal Neovascularization", "Wet Macular Degeneration" ], "interventions": [ { "name": "Tiespectus", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EyeBiotech Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 960, "start_date": "2026-03-27", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-17T16:18:45.511Z", "location_count": 64, "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Springdale, Arkansas + 56 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Glendale", "state": "California" }, { "city": "Modesto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07440225" }, { "nct_id": "NCT00964795", "title": "Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (\"Wet\") Age-related Macular Degeneration (AMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "Intravitreal Aflibercept Injection 2mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 323, "start_date": "2009-12", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2015-03-23", "last_synced_at": "2026-09-17T16:18:45.511Z", "location_count": 115, "location_summary": "Birmingham (2 Locations), Alabama • Phoenix (2 Locations), Arizona • Tucson (2 Locations), Arizona + 112 more", "locations": [ { "city": "Birmingham (2 Locations)", "state": "Alabama" }, { "city": "Phoenix (2 Locations)", "state": "Arizona" }, { "city": "Tucson (2 Locations)", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00964795" }, { "nct_id": "NCT01578720", "title": "Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Choroidal Neovascularization", "Presumed Ocular Histoplasmosis" ], "interventions": [ { "name": "EYLEA (Aflibercept) intravitreal injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Retina Research Institute, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 5, "start_date": "2012-06", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2018-08-29", "last_synced_at": "2026-09-17T16:18:45.511Z", "location_count": 3, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01578720" }, { "nct_id": "NCT00509795", "title": "Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "ranibizumab", "type": "BIOLOGICAL" }, { "name": "aflibercept injection (VEGF Trap-Eye, BAY86-5321)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1217, "start_date": "2007-08", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2012-12-28", "last_synced_at": "2026-09-17T16:18:45.511Z", "location_count": 176, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509795" }, { "nct_id": "NCT06491914", "title": "A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-Related Macular Degeneration", "Diabetic Macular Edema" ], "interventions": [ { "name": "Aflibercept 8 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1118, "start_date": "2024-07-24", "completion_date": "2027-01-07", "has_results": false, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-09-17T16:18:45.511Z", "location_count": 53, "location_summary": "Arcadia, California • Bakersfield, California • Beverly Hills, California + 48 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06491914" } ] }